This is a StreetInsider.com Premium Only Page

(GTHX) – StreetInsider.com Reports

Feb 28, 2024 06:33 AM G1 Therapeutics, Inc. (GTHX) Tops Q4 EPS by 7c ; Offers Guidance

Feb 13, 2024 07:18 AM G1 Therapeutics (GTHX) PT Lowered to $12 at Needham & Company

Feb 13, 2024 03:29 AM G1 Therapeutics (GTHX) PT Lowered to $4 at Wedbush

Feb 12, 2024 04:05 PM G1 Therapeutics (GTHX) to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis

Dec 5, 2023 09:27 AM G1 Therapeutics (GTHX) Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

Nov 2, 2023 06:43 AM G1 Therapeutics (GTHX) PT Lowered to $9 at H.C. Wainwright

Nov 1, 2023 06:33 AM G1 Therapeutics (GTHX) Misses Q3 EPS by 1c; Offers FY23 COSELA Sales Guidance

Oct 27, 2023 07:01 AM G1 Therapeutics (GTHX) Reports Data Showing Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with ES-SCLC

Oct 18, 2023 08:07 AM G1 Therapeutics' (GTHX) COSELA Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology

Oct 6, 2023 06:26 AM JPMorgan Downgrades G1 Therapeutics (GTHX) to Underweight; 'Cautious On Cosela'

Sep 18, 2023 07:00 AM Black Diamond Therapeutics (BDTX) Announces CEO Transition

Aug 2, 2023 06:34 AM G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 36c, Reiterates Guidance

May 10, 2023 07:32 AM G1 Therapeutics (GTHX) Reports New Results from Phase 2 Trial Confirm Benefit of Trilaciclib

May 3, 2023 06:36 AM G1 Therapeutics, Inc. (GTHX) Tops Q1 EPS by 11c

Mar 1, 2023 06:39 AM G1 Therapeutics, Inc. (GTHX) Tops Q4 EPS by 8c

Feb 14, 2023 06:44 AM G1 Therapeutics (GTHX) PT Lowered to $11 at H.C. Wainwright

Feb 14, 2023 05:39 AM G1 Therapeutics (GTHX) PT Lowered to $6 at BTIG

Feb 13, 2023 12:48 PM G1 Therapeutics (GTHX) PT Lowered to $18 at Needham & Company

Feb 13, 2023 10:30 AM G1 Therapeutics (GTHX) PT Lowered to $5 at Wedbush

Feb 13, 2023 06:01 AM G1 Therapeutics (GTHX) Reports Top Line Results from Phase 3 Trial of Trilaciclib

Jan 30, 2023 02:07 AM JPMorgan Upgrades G1 Therapeutics (GTHX) to Neutral

Jan 9, 2023 06:31 AM G1 Therapeutics (GTHX) Announces Upcoming 2023 Readouts from Phase 2 and Phase 3 Trials of Trilaciclib

Jan 4, 2023 04:20 PM EF Hutton Starts G1 Therapeutics (GTHX) at Buy

Jan 4, 2023 06:31 AM G1 Therapeutics (GTHX) provides initial update on PRESERVE 3

Jan 3, 2023 07:24 AM G1 Therapeutics (GTHX) PT Lowered to $31 at Needham & Company

Nov 25, 2022 06:43 AM G1 Therapeutics (GTHX) PT Lowered to $34 at H.C. Wainwright

Nov 18, 2022 05:13 AM G1 Therapeutics (GTHX) Prices 7.7M Share Offering at $6.50/sh

Nov 17, 2022 04:01 PM G1 Therapeutics (GTHX) Announces Proposed Stock Offering, Size not Disclosed

Nov 8, 2022 09:25 AM G1 Therapeutics (GTHX) PT Lowered to $7 at JPMorgan

Nov 3, 2022 06:31 AM G1 Therapeutics (GTHX) PT Lowered to $57 at H.C. Wainwright

Nov 2, 2022 06:29 AM G1 Therapeutics (GTHX) Reports Strong Phase 2 Results of Trilaciclib

Oct 26, 2022 09:27 AM G1 Therapeutics (GTHX) Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin

Sep 16, 2022 06:20 AM G1 Therapeutics (GTHX) PT Raised to $25 at Wedbush

Aug 3, 2022 11:52 AM G1 Therapeutics (GTHX) PT Raised to $35 at Roth Capital

Aug 3, 2022 06:44 AM G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 10c

Jul 25, 2022 06:31 AM G1 Therapeutics (GTHX) Appoints Norman E. Sharpless to its Board

Jul 13, 2022 10:16 AM G1 Therapeutics (GTHX) Announces COSELA Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

Jun 28, 2022 07:32 AM G1 Therapeutics (GTHX) Appoints Jacks Lee to its Board

May 4, 2022 03:51 PM G1 Therapeutics (GTHX) PT Lowered to $42 at Needham & Company

May 4, 2022 12:57 PM G1 Therapeutics (GTHX) PT Lowered to $33 at Roth Capital

Apr 26, 2022 05:59 AM Raymond James Reiterates Outperform Rating, $24 Price Target on G1 Therapeutics (GTHX) Following Latest IQVIA Sales Data

Apr 14, 2022 06:04 AM Needham & Company Reiterates Buy Rating, $44 Price Target on G1 Therapeutics (GTHX)

Feb 23, 2022 02:15 PM G1 Therapeutics (GTHX) Reiterated at Outperform by Cowen, Expect Shares to Outperform as Phase 3 Readout Approaches

Dec 16, 2021 06:02 AM G1 Therapeutics (GTHX) Expands COSELA Sales Force

Nov 12, 2021 08:25 AM G1 Therapeutics (GTHX) Phase 2 Data Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy

Nov 4, 2021 07:10 AM UPDATE: JPMorgan Downgrades G1 Therapeutics (GTHX) to Underweight

Nov 4, 2021 06:13 AM G1 Therapeutics (GTHX) PT Lowered to $71 at H.C. Wainwright

Nov 3, 2021 12:24 PM G1 Therapeutics (GTHX) PT Lowered to $54 at Roth Capital, Following Earnings

Oct 14, 2021 04:20 PM UPDATE: Correction: BTIG Assumes G1 Therapeutics, Inc. (GTHX) at Buy

Oct 14, 2021 03:55 PM G1 Therapeutics (GTHX) PT Lowered to $24 at Wedbush